Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with few treatment options.
Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with few treatment options.